Core Viewpoint - Tidewater (TDW) has shown a 7.3% increase in stock price over the past four weeks, with a mean price target of $74.8 indicating a potential upside of 31.5% from the current price of $56.88 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $20.27, indicating variability among analysts; the lowest estimate is $55.00 (3.3% decline), while the highest is $108.00 (89.9% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - There is increasing optimism among analysts about TDW's earnings prospects, as indicated by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 22.8%, with one estimate moving higher and no negative revisions [12] - TDW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a solid potential upside [13] Caution on Price Targets - While consensus price targets are often used by investors, relying solely on them may not be prudent due to historical inaccuracies in predicting stock price movements [3][7][10] - Analysts may set overly optimistic price targets influenced by business relationships, which can lead to inflated expectations [8]

Core Viewpoint - Perrigo (PRGO) shows potential for significant upside, with a mean price target of $36.67 indicating a 36% increase from the current trading price of $26.96 [1] Price Targets - The average price target consists of three estimates ranging from a low of $30.00 to a high of $42.00, with a standard deviation of $6.11, suggesting variability in analyst predictions [2] - The lowest estimate indicates an 11.3% increase, while the highest suggests a 55.8% upside [2] - A low standard deviation indicates a higher agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are increasingly optimistic about PRGO's earnings prospects, as evidenced by upward revisions in EPS estimates [11] - The Zacks Consensus Estimate for the current year has risen by 0.3% over the past month, with one estimate increasing and no negative revisions [12] - PRGO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][7] - Analysts often set optimistic price targets due to business incentives, which can lead to inflated estimates [8] - While price targets should not be ignored, they should be approached with skepticism and not be the sole basis for investment decisions [10]

Group 1 - Kiniksa Pharmaceuticals International, plc (KNSA) closed at $30.26, with an 8.5% gain over the past four weeks, and a mean price target of $41.14 suggests a 36% upside potential [1] - The mean estimate includes seven short-term price targets with a standard deviation of $7.45, indicating variability among analysts; the lowest estimate is $32.00 (5.8% increase), while the highest is $54.00 (78.5% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with a 26.6% increase in the Zacks Consensus Estimate for the current year, indicating potential upside for KNSA [11][12] Group 2 - KNSA holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for near-term upside [13] - The clustering of price targets with a low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [9] - While price targets should not be the sole basis for investment decisions, they can provide a useful starting point for further research into the stock's fundamental drivers [10][14]

Core Viewpoint - Zevra Therapeutics (ZVRA) has seen a 16.8% increase in share price over the past four weeks, closing at $10.99, with analysts suggesting a potential upside of 117.1% based on a mean price target of $23.86 [1][4]. Price Targets and Analyst Estimates - The mean price target is derived from seven short-term estimates with a standard deviation of $3.39, indicating a range of potential outcomes; the lowest estimate is $19.00 (72.9% increase), while the highest is $29.00 (163.9% increase) [2][9]. - A low standard deviation among price targets suggests a strong consensus among analysts regarding the stock's price direction, although it does not guarantee that the stock will reach the average target [9][10]. Earnings Estimates and Market Sentiment - Analysts are optimistic about ZVRA's earnings prospects, as indicated by a significant increase in earnings estimate revisions, with a 337.1% rise in the Zacks Consensus Estimate for the current year [11][12]. - ZVRA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, which supports the stock's potential for near-term upside [13]. Conclusion on Price Movement - While consensus price targets may not be entirely reliable, the positive direction indicated by earnings estimate revisions appears to be a valid guide for potential stock price movements [14].

Group 1 - Shares of uniQure (QURE) have increased by 1.3% over the past four weeks, closing at $14.46, with a mean price target of $35.09 indicating a potential upside of 142.7% [1] - The mean estimate consists of 11 short-term price targets with a standard deviation of $17.1, where the lowest estimate is $13.00 (10.1% decline) and the highest is $70.00 (384.1% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, with a positive trend in earnings estimate revisions suggesting potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1% due to one upward revision in the last 30 days, with no negative revisions [12] - QURE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - West Pharmaceutical Services (WST) has shown a significant price increase of 13.7% over the past four weeks, with analysts projecting a mean price target of $316.82, indicating a potential upside of 25.3% from the current price of $252.94 [1] Price Targets and Analyst Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $34.23, suggesting variability in analyst predictions. The lowest estimate is $260.00 (2.8% increase), while the highest is $355.00 (40.4% increase) [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding WST's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. Four estimates have increased over the last 30 days, with no negative revisions, leading to a 7.8% increase in the Zacks Consensus Estimate [11][12] - WST holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Caution on Price Targets - While price targets are commonly referenced by investors, they can often mislead. Empirical research suggests that price targets rarely indicate actual stock price movements, and analysts may set overly optimistic targets due to business incentives [7][8][10]

Group 1 - Montrose Environmental (MEG) shares have increased by 2.1% over the past four weeks, closing at $22.39, with a mean price target of $29.4 indicating a potential upside of 31.3% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $4.83, where the lowest estimate is $24.00 (7.2% increase) and the highest is $35.00 (56.3% increase) [2] - Analysts show a consensus that MEG will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for MEG has increased by 4.7% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - MEG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting the extent of MEG's gains, they can provide a directional guide for price movement [14]

Group 1 - Tango Therapeutics, Inc. (TNGX) shares have increased by 18.7% over the past four weeks, closing at $6.46, with a mean price target of $10.43 indicating a potential upside of 61.5% [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $2.23, where the lowest estimate is $8.00 (23.8% increase) and the highest is $13.00 (101.2% increase) [2] - Analysts show strong agreement on TNGX's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for TNGX has increased by 1% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - TNGX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Group 1 - Kennedy-Wilson (KW) closed at $7.6, with a 9.2% gain over the past four weeks, and a mean price target of $9.9 indicating a 30.3% upside potential [1] - The average price targets range from a low of $7.70 to a high of $13.00, with a standard deviation of $2.76, suggesting variability in analyst estimates [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for KW has increased by 109.1% due to one estimate moving higher over the last 30 days without any negative revisions [12] - KW holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement [14]

Group 1 - Revolution Medicines, Inc. (RVMD) shares have increased by 2.7% over the past four weeks, closing at $37.91, with a mean price target of $72.25 indicating a potential upside of 90.6% [1][2] - The mean estimate consists of 12 short-term price targets with a standard deviation of $7.86, where the lowest estimate is $57.00 (50.4% increase) and the highest is $88.00 (132.1% increase) [2] - Analysts show strong agreement on RVMD's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for RVMD's current year earnings has increased by 1% over the last 30 days, with one estimate moving higher and no negative revisions [12] - RVMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]